Printer Friendly

GENETICS INSTITUTE AND SCIGENICS PLAN TO FILE AMENDED PROTOCOL FOR TESTING OF M-CSF AS CHOLESTEROL LOWERING AGENT

 GENETICS INSTITUTE AND SCIGENICS PLAN TO FILE AMENDED PROTOCOL
 FOR TESTING OF M-CSF AS CHOLESTEROL LOWERING AGENT
 CAMBRIDGE, Mass., Oct. 28 /PRNewswire/ -- Genetics Institute, Inc. (NASDAQ: GENIZ) and SciGenics, Inc. (NASDAQ: SCGN) announced today that, after recent discussions with the FDA, Genetics Institute plans to file an amended protocol to permit the initiation of a clinical study of M- CSF in cholesterol lowering. The initiation of the study has been on hold due to questions raised by the FDA earlier this year in response to Genetics Institute's initial IND submission for this study.
 "We plan to amend our protocol filing in response to discussions with the FDA regarding the initiation of this study," said Dr. Patrick Gage, executive vice president of Genetics Institute. "If our protocol amendment meets with FDA approval, we would expect to initiate a study in the first half of 1993 that is designed to demonstrate the safety of M-CSF at effective doses for cholesterol lowering in severely affected individuals," he added.
 The principal objective of the planned study is to evaluate the safety of M-CSF as an agent to lower cholesterol levels in patients with a genetic predisposition to extremely high blood cholesterol levels. This clinical condition is referred to as homozygous familial hypercholesterolemia and involves a small patient group of 200-300 people in the United States.
 The patent and technology rights to M-CSF for North America were licensed to SciGenics, Inc. in May 1991. Schering-Plough holds the exclusive license for M-CSF in Europe, Africa and South America. Morinaga Milk Industry Company, Ltd. holds an exclusive license for M-CSF in Japan.
 Genetics Institute (NASDAQ: GENIZ) is a leading biopharmaceutical firm engaged in the discovery and development of human pharmaceuticals through recombinant DNA and other technologies. SciGenics (NASDAQ: SCGN) went public in 1991 to further the development and clinical evaluation of recombinant M-CSF and to conduct early stage research and development of embryonic growth and regulatory proteins.
 -0- 10/28/92
 /CONTACT: Melinda Lindquist or Gina Price, Genetics Institute corporate communications, 617-876-1170/
 (GENIZ SCGN) CO: Genetics Institute, Inc.; SciGenics, Inc. ST: Massachusetts IN: MDC SU: CON


CN -- NE002 -- 5786 10/28/92 08:39 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 28, 1992
Words:358
Previous Article:FORD CREDIT REPORTS RECORD EARNINGS
Next Article:VARITY INITIATIVES INCLUDE EQUITY OFFERING AND SALE OF 50.2 PERCENT OF KELSEY-HAYES WHEELS UNIT TO PUBLIC
Topics:


Related Articles
GENETICS INSTITUTE AND SCIGENICS ANNOUNCE DELAY IN M-CSF CHOLESTEROL STUDIES
GENETICS INSTITUTE PLANS $55 MILLION FACILITY EXPANSION IN MASSACHUSETTS
GENETICS INSTITUTE AND SCIGENICS PLAN TO FILE AMENDED PROTOCOL FOR TESTING OF M-CSF AS CHOLESTEROL LOWERING AGENT
GENETICS INSTITUTE - YAMANOUCHI JOINT VENTURE TO MARKET rhIL-11 IN JAPAN
GENETICS INSTITUTE AND SCIGENICS RECEIVE FDA GO AHEAD ON M-CSF CHOLESTEROL STUDY
PATRICK GAGE, PH.D. TO BECOME GENETICS INSTITUTE'S CHIEF OPERATING OFFICER; OTHER OFFICERS APPOINTED
GENETICS INSTITUTE PROPOSES ACQUISITION OF SCIGENICS
GENETICS INSTITUTE SIGNS DEFINITIVE MERGER AGREEMENT WITH SCIGENICS
SCIGENICS SIGNS DEFINITIVE MERGER AGREEMENT WITH GENETICS INSTITUTE
GENETICS INSTITUTE COMPLETES ACQUISITION OF SCIGENICS, INC.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters